Panelists discuss how emerging therapies like menin inhibitors show promise based on strong preclinical data and clinical responses, while CD47 inhibitors have faced setbacks in phase 3 trials, with ...
The MarketWatch News Department was not involved in the creation of this content. No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently ...
Panelists discuss how oral azacitidine plus venetoclax represents a transformative advance toward completely oral regimens that could dramatically improve quality of life and accessibility, though ...
Aptevo Therapeutics (NASDAQ:APVO) saw its stock jump 57% on Tuesday after announcing that Cohort 3 of its Phase 1b/2 RAINIER trial for acute myeloid leukemia (AML) achieved a 100% remission rate. The ...
LYT-200 continues to demonstrate strong evidence of clinical activity, survival benefit and a highly favorable safety profile in heavily pretreated relapsed/refractory AML patients, both as a ...
The 100% remission rate (CR/CRi) achieved at the highest dose level of the RAINIER trial to date demonstrates mipletamig's potential to redefine the frontline treatment landscape for newly diagnosed ...
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) ...
SEATTLE, WA / ACCESS Newswire / September 16, 2025 / Aptevo Therapeutics ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company developing novel bispecific and trispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback